Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 16
2004 21
2005 4
2006 14
2007 14
2008 25
2009 19
2010 15
2011 14
2012 19
2013 22
2014 30
2015 28
2016 9
2017 16
2018 16
2019 23
2020 37
2021 43
2022 29
2023 34
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

388 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Hussain M, et al. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. N Engl J Med. 2020. PMID: 32955174 Free article. Clinical Trial.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
This issue 30-1.
Fujii Y. Fujii Y. Int J Urol. 2023 Jan;30(1):6. doi: 10.1111/iju.15118. Int J Urol. 2023. PMID: 36702787 No abstract available.
Editorial Comment.
Tanaka H, Fujii Y. Tanaka H, et al. Among authors: fujii y. J Urol. 2021 May;205(5):1319-1320. doi: 10.1097/JU.0000000000001549.02. Epub 2021 Feb 24. J Urol. 2021. PMID: 33625924 No abstract available.
[Prostate cancer].
Fujii Y, Fukui I. Fujii Y, et al. Gan To Kagaku Ryoho. 2007 Nov;34(11):1740-4. Gan To Kagaku Ryoho. 2007. PMID: 18030007 Review. Japanese.
Heterogeneous circulating miRNA profiles of PBMAH.
Hara K, Murakami M, Niitsu Y, Takeuchi A, Horino M, Shiba K, Tsujimoto K, Komiya C, Ikeda K, Tsuiki M, Tanabe A, Tanaka T, Yokoyama M, Fujii Y, Naruse M, Yamada T. Hara K, et al. Among authors: fujii y. Front Endocrinol (Lausanne). 2022 Dec 13;13:1073328. doi: 10.3389/fendo.2022.1073328. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36583003 Free PMC article.
DWI as an Imaging Biomarker for Bladder Cancer.
Yoshida S, Takahara T, Kwee TC, Waseda Y, Kobayashi S, Fujii Y. Yoshida S, et al. Among authors: fujii y. AJR Am J Roentgenol. 2017 Jun;208(6):1218-1228. doi: 10.2214/AJR.17.17798. Epub 2017 Feb 28. AJR Am J Roentgenol. 2017. PMID: 28245143 Review.
388 results